Searchable abstracts of presentations at key conferences in endocrinology

ea0020p217 | Endocrine tumours and neoplasia | ECE2009

The ectopic adrenocorticotropic hormone syndrome in carcinoid tumors (case report)

Gabidzashvili Nino , Vinogradskaya Olga , Zykova Polina , Pronin Vyatcheslav

Ectopic production of adrenocorticotropic hormone by carcinoid tumors is relatively uncommon. This report describes a woman who had Cushing syndrome from the ectopic secretion of adrenocorticotropic hormone by a carcinoid tumor. Before her hospitalization the patient’s conditions was misdiagnosed as disease of connective tissue and thus the patient was treated inadequately. The untreated hypercortisolism caused bilateral pneumonia and sepsis. There are three instructive e...

ea0035p912 | Pituitary Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2014

Efficacy and safety of lanreotide autogel (LAN-ATG) 120 mg at extended dosing intervals (EDIs) in acromegalic patients biochemically controlled with octreotide LAR (OCT-LAR) 10 or 20 mg: The LEAD study

van der Lelij Art-Jan , Pronin Vyatcheslav , Balcere Inga , Lee Moon-Kyu , Rozhinskaya Liudmila , Bronstein Marcello , Gadelha Monica , Maisonobe Pascal , Sert Caroline

Introduction: EDIs with LAN-ATG therapy may help improve the burden associated with long-term acromegaly management. The LEAD study evaluated the efficacy and safety of this approach by switching from OCT-LAR conventional dosing to LAN-ATG EDI.Methods: LEAD was a multinational, multicentre, open-label, non-comparative study. Acromegalic patients with normal IGF1 after OCT-LAR 10 or 20 mg injections every 4 weeks for ≧6 months were switched to LAN-...